Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) shares traded up 11.8% during trading on Tuesday . The company traded as high as $2.30 and last traded at $2.18. 58,610 shares were traded during mid-day trading, a decline of 2% from the average session volume of 60,003 shares. The stock had previously closed at $1.95.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.
View Our Latest Report on MENS
Jyong Biotech Trading Down 4.1%
Jyong Biotech (NASDAQ:MENS – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Jyong Biotech during the third quarter valued at $67,000. Geode Capital Management LLC raised its position in Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after buying an additional 10,538 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Jyong Biotech during the fourth quarter valued at $49,000. Millennium Management LLC acquired a new position in Jyong Biotech during the third quarter valued at $512,000. Finally, Man Group plc acquired a new position in Jyong Biotech during the fourth quarter valued at $56,000.
Jyong Biotech Company Profile
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Further Reading
- Five stocks we like better than Jyong Biotech
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Jyong Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jyong Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
